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Abstract
Background: Serotype-specific polysaccharide based group B streptococcus (GBS) vaccines are being developed. An
understanding of the serotype epidemiology associated with maternal colonization and invasive disease in infants is
necessary to determine the potential coverage of serotype-specific GBS vaccines.
Methods: Colonizing GBS isolates were identified by vaginal swabbing of mothers during active labor and from skin of their
newborns post-delivery. Invasive GBS isolates from infants were identified through laboratory-based surveillance. GBS
serotyping was done by latex agglutination. Serologically non-typeable isolates were typed by a serotype-specific PCR
method. The invasive potential of GBS serotypes associated with sepsis within seven days of birth was evaluated in
association to maternal colonizing serotypes.
Results: GBS was identified in 289 (52.4%) newborns born to 551 women with GBS-vaginal colonization and from 113 (5.6%)
newborns born to 2,010 mothers in whom GBS was not cultured from vaginal swabs. The serotype distribution among vaginal-
colonizingisolateswasasfollows: III(37.3%),Ia(30.1%),andII(11.3%),V(10.2%),Ib(6.7%)andIV(3.7%). Therewere nosignificant
differences in serotype distribution between vaginal and newborn colonizing isolates (P=0.77). Serotype distribution of invasive
GBS isolates were significantly different to that of colonizing isolates (P,0.0001). Serotype III was the most common invasive
serotype in newborns less than 7 days (57.7%) and in infants 7 to 90 days of age (84.3%; P,0.001). Relative to serotype III, other
serotypes showed reduced invasive potential: Ia (0.49; 95%CI 0.31–0.77), II (0.30; 95%CI 0.13–0.67) and V (0.38; 95%CI 0.17–0.83).
Conclusion: In South Africa, an anti-GBS vaccine including serotypes Ia, Ib and III has the potential of preventing 74.1%,
85.4% and 98.2% of GBS associated with maternal vaginal-colonization, invasive disease in neonates less than 7 days and
invasive disease in infants between 7–90 days of age, respectively.
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Introduction
Group B streptococcus (GBS) has been identified as a major
cause of neonatal infection since the 1970s [1,2]. GBS acquisition
by newborns from maternal recto-vaginal colonization is an
established risk factor for GBS sepsis within the first 7 days of life
[3]. Vertical acquisition of GBS, involving colonization of the skin
or mucous membranes, occurs in 15% to 50% of newborns born
to GBS colonized mothers. An estimated 1–2% of newborns
colonized by GBS develop invasive disease [4,5].
Maternal vaccination against GBS, aimed at possibly reducing
maternal colonization and enhancing transplacental transfer of
anti-GBS antibody to the foetus, is being explored to prevent GBS
associated sepsis during early infancy [6,7]. The success of
maternal immunization in preventing young infant morbidity
and mortality is best characterized by the success of tetanus
immunization program and inactivated influenza vaccine studies
during pregnancy [8,9].
GBS serotype specific polysaccharide-protein conjugate vaccine
candidates, including serotypes Ia, Ib and III, have been evaluated
for safety and immunogenicity [6,10]. These vaccines are expected
to provide serotype specific protection, hence, the need to
undertake serotype characterization of colonizing and invasive
GBS isolates, and estimating the invasive potential of individual
serotype. GBS serotyping is based on the identification of specific
capsular polysaccharide (CPS) epitopes (Ia, Ib, II to IX) [11,12].
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17861There are limited data on GBS serotype epidemiology associated
with recto-genital maternal colonization or invasive disease in
infants from industrializing countries.
We aimed to: i. study the serotype distribution of GBS isolates
associated with colonization in mother-newborn dyads; ii.
characterize the capsular serotype distribution of invasive isolates
from infants; and iii. compare the relative invasive potential of
GBS serotypes associated with early-onset disease.
Materials and Methods
Ethics Statement
Analysis of the GBS isolates for this study was approved by the
Human Research Ethics Committee on Human Subjects (HREC)
at the University of the Witwatersrand. Signed informed consent
for collection of the isolates was obtained from study participants
of the PoPS study, which was also approved by the HREC. The
PoPS study was registered in ClinicalTrials.gov (Trial number:
NCT00136370).
Study Population
The study was conducted at a secondary-tertiary care hospital
(Chris Hani-Baragwanath Hospital; CHBH) which provides
health care to an urban population of 1.5 million indigenous
Africans living in Soweto, South Africa. There are approximately
28 000 births annually in Soweto, 75% are born at CHBH and the
remainder at one of seven surrounding primary health care clinics.
The majority of Sowetan children requiring hospitalization are
admitted at CHBH.
GBS isolates from mother-newborn dyads were identified from
participants involved in the Prevention of Perinatal Sepsis (PoPS)
trial undertaken at CHBH between April 2004 to October 2007 as
reported [13]. Briefly, mothers were randomized during active
labor for intra-vaginal chlorhexidine washes (0.5%) or external
genitalia wipes with water. Vaginal swabs were undertaken prior
to initiation of any study procedure and swabs were obtained from
the newborn’s ears, nose and umbilicus shortly after birth. The
swabs were transported in Amies medium and processed using
standard microbiological assays as described [13]. The PoPS study
indicated that intra-vaginal chlorhexidine wipes were not
associated with any reduction in vertical acquisition of GBS in
the newborns. [13] Serotyping in this study was, nevertheless,
limited to mother-newborn dyads who had been randomized to
the placebo arm of the PoPS trial.
In addition, prospective surveillance of early infant sepsis at
CHBH was undertaken from January 2004 to December 2008.
GBS isolates from blood and cerebrospinal fluid (CSF) from
infants with invasive disease, identified as part of routine medical
care, were retrieved from the laboratory. The isolates were stored
at 270uC in a broth containing skim milk, tryptone, glucose and
glycerol (STGG) at the Respiratory and Meningeal Pathogens
Research Unit., Johannesburg, South Africa, where serotyping
was subsequently undertaken.
Latex agglutination capsular serotyping
Capsular serotyping was performed with the latex agglutination
method with specific antisera against types Ia, Ib and II to IX CPS
antigens (Statens Serum Institute, SSI, Sweden) as previously
described by Slotved et al [14]. Isolates that were reactive to sera
against serotype III were further tested with sera against serotype
VI to test for cross reactivity. Isolates that tested negative with all
antisera were designated as serologically non-typeable and further
typed by PCR. The GBS strains Ia (SSI-615), Ib (SS-618), II (SS-
619), III (SS-620), IV (SS-1243), V (SS-1168), VI (SS-1354), VII
(SS-1355), VIII (SS-1356), and IX (27412) were used as serotype
specific control strains.
Molecular capsular typing
Isolates designated as non-typeable by latex agglutination were
characterized by a molecular capsular typing assay. DNA was
extracted with the QIAamp DNA mini kit (Qiagen GmbH, USA)
as per manufacture’s recommendation. Capsular typing was
performed with a singleplex PCR method for serotypes Ia, Ib,
II, II, IV and V using primer sequences reported by Poyart et al
[15]. The gene encoding dlts was used as a positive control for
GBS identification.
Statistical analysis
Data were analyzed using Graphpad Prism version 4.01 and
STATA version 8.0. Serotype distribution between maternal and
neonatal colonizing strains, and strains causing invasive disease
was determined by a two tailed Fisher’s exact test. Logistic
regression was used to determine the association of frequency of
serotypes in relation to the timing of onset of infant sepsis and
disease syndrome.
As maternal colonization is a primarily risk factor for early onset
(,7days of age) GBS disease, analyses of the invasive potential of
GBS isolates was restricted to episodes within 7 days of birth and
serotype associated with late onset ($7 days of age) were excluded.
Invasive potential of individual serotypes was estimated by
calculating odds ratio (OR) using serotype III as a fixed reference
serotype, since it has been consistently shown to be the most
prevalent serotype in both colonizing and invasive disease isolates.
This method has an advantage over calculating OR by reference
to all other serotypes because the resulting estimate is a robust
measure of invasive potential. The relative serotype-specific
invasive potential was calculated based on the formula of odds
ratio (OR) = (ad)/(bc) as described by Brueggemann et al [16].
Where ‘‘a’’ is the number of early onset isolates of a specific
serotype; ‘‘b’’ is the number of early onset isolates of serotype III;
‘‘c’’ is the number of that specific serotype from maternal
colonization isolates; and ‘‘d’’ is the number of serotype III from
maternal colonization isolates. Associated 95% confidence inter-
vals (95% CI) were estimated. Where two isolates of the same
serotype were obtained from the same infant, only one isolate was
included in the analysis.
Results
Overall, GBS was identified from the vagina of 551 (21.5%) of 2
561 mothers and from the skin/mucosal surface of 402 (15.8%) of 2
542newbornsbornmotherswho were swabbed.GBSwasidentified
in 289 (52.5%) newborns of the 551 mothers who were identified to
be vaginally colonized by GBS during labor. In addition, GBS was
also identified in a further 113 (5.6%) newborns born to 2,010
mothers in whom GBS was not detected on vaginal swabbing.
A total of 284 GBS isolates were obtained from 282 infants with
invasive disease. These included 222 from blood (77.5%), and 62
from CSF (21.1%). GBS isolates were obtained from blood and
CSF from two infants. The age distribution of infants with invasive
isolates included 137 (48.2%) under 7 days of age, 108 (38.0%)
between 7 to 90 days of age and 39 (13.7%) from children older
than 90 days of age.
Serotype distribution of maternal and newborn
colonizing isolates
Serotyping was done on 541 (98.2%) of 551 available isolates
obtained from colonized mothers and on 396 (98.5%) of 402
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differences in the serotype distribution (data not shown) between
isolates from HIV-infected women (n=119) compared to HIV-
uninfected women (n=418; P=0.55). A total of 106 (19.6%)
maternal and 76 (19.2%) newborn colonizing GBS isolates were
serologically non-typeable (Table 1). Molecular capsular typing
was successful in identifying a capsular serotype gene in 173
(95.1%) of the 182 serologically non-typable colonizing isolates
(Table 1). The frequency of serotype distribution between
serologically typeable isolates compared to those only typable by
PCR differed as follows: Ia (32.4% vs. 14.8%, respectively;
P,0.0001), Ib (2.4% vs. 23.1%, respectively; P,0.0001), II
(13.3% vs. 4.4%, respectively; P=0.0004), III (40.3% vs. 22.5%,
respectively; P,0.0001); IV (1.3% vs. 15.4%, respectively;
P,0.0001) and V (10.3% vs. 14.8%, respectively; P=0.09).
Overall, of the colonizing isolates, serotype III was the most
common in mothers (37.3%) and newborns (36.2%) (Table 1).
Collectively, serotypes Ia, Ib and III accounted for 74.1% (401/
541) of maternal and 69.6% (275/395) of newborn colonizing
isolates. There were no differences in the relative frequencies of
any of the serotypes between colonized mothers and colonized
newborns. Isolates were available for serotyping from 280 (96.9%)
of 289 mother-newborn pairs who were both colonized with GBS,
among which there was 90.7% (254/280) concordance in serotype
between the mother and newborn isolates. In addition, invasive
GBS disease as a result of serotype III (n=3) and Ia (n=3)
occurred in six newborns less than 7 days of age in whom
colonizing isolates were available from the mother and the
newborn, of which the invasive serotype was identical to the
colonizing serotype in all of these newborns.
Serotype distribution of invasive GBS isolates
The dominant serotypes causing invasive disease in infants less
than 7 days and in those aged between 7 to 90 days were serotype
III (57.7% vs. 84.3%, respectively; P,0.0001) and serotype Ia
(22.6% vs. 13.9%, respectively; P=0.01). Together, these sero-
types accounted for 80.3% of invasive GBS disease occurring in
neonates less than 7 days of age and 98.2% of invasive disease
occurring in infants aged 7 to 90 days. Serotypes III and Ia
together accounted for 53.9% of invasive GBS isolates occurring
in children older than 90 days of age. Individually, serotypes Ib, II,
IV, and V accounted for less than 6% of invasive isolates in infants
less than 7 days of age and in infants aged 7 to 90 days. No
invasive isolate was reactive to sera against serotypes VI, VII, VIII
and IX. After adjusting for the type of specimen from where the
isolate was recovered (i.e. blood only vs. CSF) and age group,
serotype III remained the dominant cause of invasive disease in
infants aged 7 to 90 days (Adjusted odds ratio: 3.60; 95%CI 1.91–
6.78; P,0.0001).
Serologically non-typeable isolates were less common from
invasive GBS isolates (20/284; 7.0%) compared to maternal or
newborn colonizing isolates. Genotypic serotyping by PCR was
successful in attributing a serotype to all serologically non-typeable
invasive isolates (Table 2).
Estimates of the relative invasive potential of serotypes
There were significant differences in the serotype distribution
between invasive isolates from neonates younger than 7 days and
maternal colonizing isolates. A higher proportion of newborn
invasive isolates in those less than 7 days age were serotype III (79/
137; 57.7%) compared to maternal colonizing isolates (202/537;
37.6%; P,0.0001). Conversely comparing invasive isolates in
newborns under 7 days to maternal colonizing isolates, serotype II
[7/137 (5.1%) vs. 61/537 (11.3%); respectively, P=0.0008] and
serotype V [8/137 (5.8%) vs. 55/537 (10.2%), respectively;
P=0.014] were less common as invasive isolates (Table 3).
Discussion
To our knowledge this study provides the most in-depth insight
of the serotype epidemiology of colonizing isolates in mother-
newborn dyads and invasive GBS isolates in an industrializing
country setting, and particularly from Africa. Although there are
extensive data on maternal colonizing serotype distribution from
industrialized countries [17,18], there are limited data comparing
serotype distribution from colonized mothers and their newborns
from industrializing countries [19,20]. The findings from our study
are similar to those reported elsewhere, [5,19,20] and confirm that
maternal GBS vaginal-colonization is commonly (52.5%) associ-
ated with infant colonization. The vertical transmission of GBS
from mother to the newborn was corroborated by the high
concordance of matching serotypes in the colonized mother-
Table 1. Serotype distribution among maternal and newborn colonizing Group B streptococcus isolates.
Serotype Maternal colonization isolates Neonatal colonization isolates
P value
Comparing total of
maternal vs. newborn
serotypes
Latex
no=541
(%)
PCR
3
no=106
Total
no=541
Latex
no=395
PCR
no=76
Total
no=395
Ia 146 (27.0)
1 17 (16.0) 163 (30.1) 98 (24.8) 10 (13.2) 108 (27.3) P=0.38
Ib 12 (2.2) 24 (22.6) 36 (6.7) 6 (1.5) 18 (23.7) 24 (6.1) P=0.79
II 55 (10.2) 6 (5.7) 61 (11.3) 45 (11.4) 2 (2.6) 47 (11.9) P=0.84
III 177 (32.7) 25 (23.6) 202 (37.3) 127 (32.2) 16 (21.1) 143 (36.2) P=0.73
IV 5 (0.9) 15 (14.2) 20 (3.7) 5 (1.3) 13 (17.1) 18 (4.6) P=0.51
V 40 (7.4) 15 (14.2) 55 (10.2) 38 (9.6) 12 (15.8) 50 (12.7) P=0.61
Non typeable 106 (19.6) 4 (3.8) 76 (19.2) 5 (6.6) P=0.22
1Molecular serotype identification by PCR was done by primers targeting serotypes 1a to V.
doi:10.1371/journal.pone.0017861.t001
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(28.1%) of 402 colonized newborns born to mothers in whom GBS
was not identified by vaginal swabbing.
The latter, as well as the incomplete, albeit high, concordance in
serotypes distribution associated with colonization in mother-
newborn dyads in our study may be due to the limitations of the
study in the sensitivity of identifying maternal colonization,
limitations in detecting concurrent multiple colonizing serotypes,
or possibly acquisition of GBS from non-maternal sources during
or soon after birth [21]. The exclusion of rectal swabs to detect
GBS colonization may have compromised the sensitivity in
detecting GBS colonization [22]. Previous studies have reported
that the sensitivity of detecting GBS colonization in pregnant
women by undertaking both rectal and vaginal swabs is 18.5%–
51% higher compared to taking vaginal swabs alone [23–27] and
suggests that maternal rectal colonization may be important
source for acquisition of GBS in newborns. Additionally, the yield
of GBS on vaginal swabbing undertaken after the onset of labor
may have been affected by draining liquor following the rupture of
the placental membranes. Consequently, our study provides a
minimal estimate as to the prevalence of GBS colonization in
pregnant women during labor, as well as the proportion of
colonized newborns who have acquired GBS from their mothers.
The serotype distribution identified in invasive isolates in our
study are consistent with other smaller studies on invasive isolates
elsewhere from Sub-Saharan Africa such as in Malawi [28],
Zimbabwe [29], and an earlier study at the same centre as this
study from 1997–1998. [30]) The serotype data of invasive isolates
from this study are nevertheless important as it confirms the
absence of temporal variation in serotype distribution of invasive
isolates over more than a decade in the study-setting. [30] This has
positive implications for the design of serotype-specific polysac-
charide vaccines for prevention of newborn GBS sepsis.
Serotype III was responsible for 69.4% of invasive GBS disease
among infants under the age of 90 days, which is in keeping with
other studies from Sub Saharan Africa (56.0–58.3%) [28,30].
Serotype Ia was the second most frequently identified invasive
serotype in infants under 90 days of age in our study (18.8%),
consistent with previous studies from South Africa (28.7%) and
Malawi (21%) [28,30]. These findings are also consistent with
serotype distribution data of invasive isolates in young infants from
industrialized countries (44% to 65% for serotype III and 33% to
15% for serotype Ia) [31–34]. Overall, 85.4% and 98.2% of
invasive isolates in children less than 7 days and those aged 7 to 90
days of age, respectively belonged to serotypes Ia, Ib or III, which
are currently being considered as serotypes to be included in a
polysaccharide-protein conjugate vaccine against GBS [6,10].
Similarly a trivalent serotype-specific GBS vaccine including these
serotypes would provide potential cover against at least 80% of
invasive serotypes in young infants in USA and European
countries [31–34].
Our data indicated that serotype III (OR=2.29) was the most
invasive of all studied serotypes based on a method of analysis
described by Brueggemann et al. [35]. These data are also
consistent with findings from Portugal (OR=1.42) [34], Sweden
(OR=2.61) [31], and Israel (OR=1.84) [36] where the same
Table 3. Estimation of invasive potential of Group B streptococcus (GBS) serotypes in different countries.
Serotype Country
South Africa Portugal [34] Israel [36] Sweden [31] Netherlands [37] Taiwan [37]
Ia 163
a/31
b
(0.49; 0.31–0.77)
c
42/13
(1.52; 0.63–3.67)
12/10
(1.14; 0.41–3.18)
15/20
(1.37; 0.61–3.10)
24/6
(0.52; 0.63–3.67)
13/5
(0.22; 0.07–0.70)
Ib 36/7
(0.50; 0.22–1.18)
14/1
(0.35; 0.04–2.93)
9/2
(0.30; 0.05–1.57)
15/2
(0.14 0.03–0.64)
ND 5/2
(0.22; 0.04–1.27)
II 61/7
(0.30 0.13–0.67)
46/8
(0.85; 0.32–2.27)
23/14
(0.83; 0.34–2.03)
13/4
(0.32; 0.09–1.07)
ND ND
III 202/78
(1.00)
59/12
(1.00)
26/19
1.00
36/35
(1.00)
20/33
(1.00)
19/34
(1.00)
IV (20/5)
(0.65; 0.23–1.79)
6/1
(0.81; 0.09–7.44)
ND 3/2
(0.69; 0.11–4.36)
ND ND
V 55/8
(0.38; 0.17–0.83)
59/7
(0.58; 0.21–1.59)
18/9
(0.68; 0.25–1.85)
25/7
(0.29; 0.11–0.75)
14/4
(0.17; 0.05–0.60)
15/2
(0.07; 0.02–0.36)
In our data two isolates of the same serotype (i.e III) were obtained from the same infant, and only one isolate was included in the analysis.
aValue indicates colonizing isolates.
bValue indicates neonatal invasive isolates.
cValue in parenthesis indicates OR and 95% CI.
dND: No data for either invasive, colonization or both isolates.
doi:10.1371/journal.pone.0017861.t003
Table 2. Serotype distribution among invasive disease
isolates from early onset (EOS; ,7 days of age), late onset
diseases (LOD; 7 to 90 days of age) and in children older than
90 days.
Serotype
Early Onset
no=137
Late Onset
no=108
.90 days age
no=39
P value
EOS vs
LOD
Ia 31 [1]
1 (22.6)
2 15 [1] (13.9) 9 [0] (23.1) P=0.99
Ib 7 [2] (5.1) 0 [0] (0) 6 [2] (15.4) P=0.009
II 7 [2] (5.1) 0 [0] (0) 6 [2] (15.4) P=0.009
III 79 [3] (57.7) 91 [3] (84.3) 12 [1] (30.8) P,0.0001
IV 5 [1] (3.6) 0 [0] (0) 0 [0] (0) P=0.07
V 8 [0] (5.8) 2 [1] (1.9) 6 [2] (15.4) P=0.19
NT 0 0 0
1Figure in squared parenthesis indicates number of isolates which were
serologically non-reactive but typed by PCR.
2Figure in rounded parenthesis is a percentage.
doi:10.1371/journal.pone.0017861.t002
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invasive potential of other serotypes with type III as a referent
serotype [16] as summarized in Table 3. The data consistently
reports that serotype Ib, II and V, are less invasive than serotype
III. However, the invasive potential of serotype Ia is variable
across different sites. In South Africa, Taiwan and The Nether-
lands [37], serotype Ia was less invasive than type III, although
more invasive in Portugal [34], Israel [36] and Sweden [31]. The
reasons for variation in invasive potential of serotype Ia reported at
different sites are unclear, however data from Portugal suggests
that the high invasive index of this serotype can be attributed to a
dominant clone (ST-23 and ST-24), suggesting that the underlying
genotype can influence the invasive potential.
Serotype V was identified in a low proportion of invasive
isolates (5.6%) in our study, which is consistent with earlier studies
from South Africa (5.6%) and Malawi (4.0%) [28,30]. In the
United States, serotype V is responsible for a high proportion of
the invasive cases among infants (28%) [38]. Similarly, a higher
prevalence of serotype V has also been reported in studies from
England and Wales (13%) [39].Recent identification of these
historically uncommon circulating strains in both colonization and
invasive disease isolates raises questions as to whether introduction
of a vaccine composed of the most common invasive serotypes
could cause a shift in serotype distribution in colonization, and
thus disease. This warrants the need for ongoing international
surveillance of invasive GBS serotypes in order to optimize GBS
vaccine formulations.
Our study demonstrated differences between serotype epidemi-
ology of isolates associated with invasive disease in newborns
compared to maternal colonizing isolates. These findings corrob-
orate the finding of other studies from industrialized country
settings [31,34,36,37]. Our study, however, clarified that the
difference in serotype distribution between invasive and colonizing
isolates is related to an increased invasive potential of certain GBS
serotypes (i.e. III and Ia) rather than due to increased risk of
acquisition of these by the newborn from the mother.
Despite the success of intrapartum antibiotic prophylaxis in
reducing GBS associated neonatal sepsis in industrialized
countries, the high costs and resource intensiveness is prohibitive
in industrializing countries [40]. Further limitations to this
intervention strategy include concerns about the emergence of
antimicrobial resistance in GBS, and a lack of efficacy in reducing
GBS sepsis in infants older than 7 days of age [41]. As a result,
neonatal morbidity due to GBS remains a public-health problem.
In Sub-Saharan Africa GBS neonatal disease occurs in 3.06 per
1,000 live births in South Africa [30], and 1.81 per 1,000 live
births in Malawi [28]. Consequently, the agenda of maternal
immunization with GBS vaccines aimed at either reducing
maternal recto-anal colonization, or preventing disease in the
newborns through transplacental antibody transfer, needs to be
explored in settings with a high burden of GBS disease.
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